false
Catalog
The Lead Episode 28: Results of the FRAIL-AF Rando ...
The Lead Episode 28 Speaker Information
The Lead Episode 28 Speaker Information
Back to course
Pdf Summary
The article being discussed is about the safety of switching from a Vitamin K Antagonist (VKA) to a Non-Vitamin K Antagonist Oral Anticoagulant (NOAC) in frail older patients with atrial fibrillation. The study, called FRAIL-AF, was a randomized controlled trial that aimed to evaluate the safety of switching anticoagulation therapy in this population.<br /><br />The authors of the article include Linda P.T. Joosten, MD, Sander van Doorn MD, PhD, and other medical professionals. The article was published in Circulation: AHA Journals.<br /><br />The discussion is hosted by William H. Sauer, MD, FHRS, CCDS, from Brigham and Women's Hospital. Other contributors include Christian Thomas Ruff, MD, MPH, and Erik Andrews, MD, MPH, also from Brigham and Women's Hospital.<br /><br />In terms of disclosures, Erik Andrews and William H. Sauer have received honoraria, speaking fees, and consulting fees from various medical companies. They have also conducted research funded by Medtronic. Christian Thomas Ruff has received honoraria, speaking fees, and consulting fees from pharmaceutical companies and has conducted research funded by Daiichi and MedImmune.<br /><br />Overall, the focus of the discussion is on the safety and implications of switching anticoagulation therapy in frail older patients with atrial fibrillation.
Keywords
Vitamin K Antagonist
Non-Vitamin K Antagonist Oral Anticoagulant
frail older patients
atrial fibrillation
FRAIL-AF
safety
anticoagulation therapy
Circulation: AHA Journals
Brigham and Women's Hospital
implications
Heart Rhythm Society
1325 G Street NW, Suite 500
Washington, DC 20005
P: 202-464-3400 F: 202-464-3401
E: questions@heartrhythm365.org
© Heart Rhythm Society
Privacy Policy
|
Cookie Declaration
|
Linking Policy
|
Patient Education Disclaimer
|
State Nonprofit Disclosures
|
FAQ
×
Please select your language
1
English